TVI-Brain-1 for the Treatment of Glioblastoma

Our lead product candidate, TVI-Brain-1, treats glioblastoma (a form of brain cancer) and is supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.   

Clinical Trial for Brain Cancer  
TVAX initiated a Phase 2b study in newly diagnosed surgically resectable O6-methylguanine methyltransferase negative (MGMT unmethylated) glioblastoma patients in 2023. The clinical study is being conducted at academic and corporate hospital clinical sites around the US.  

Clinical Data for TVI-Brain-1

TVAX Immunotherapy has been evaluated in Phase 1/2 clinical trials in 43 patients with recurrent grade 3 and grade 4 gliomas who previously failed surgery, radiotherapy and chemotherapy.  Results of these studies demonstrated significantly increased median survival for patients treated with TVAX Immunotherapy as compared to historical controls.

Scroll to Top